Keyphrases
Randomized Placebo-controlled Trial
100%
Liraglutide
100%
Glycemic Control
100%
Overweight Adults
100%
Adult Patients
100%
Type I Diabetes
100%
Type 1 Diabetes Mellitus (T1DM)
100%
Placebo
60%
Glucagon-like
25%
Between-group
25%
Hemoglobin A1c (HbA1c)
20%
Glucagon
15%
Insulin Dose
15%
Hypoglycemic Events
15%
Heart Rate
15%
Insulin
15%
Glycemic Variability
10%
Hypoglycemia
10%
Receptor Agonist
10%
A1 Receptor
10%
End of Treatment
10%
Gastric Emptying
10%
Between-group Difference
10%
Patient-Reported Outcomes Measurement Information System (PROMIS)
10%
Vomiting
5%
Treatment Assignment
5%
Safety Analysis
5%
Normoglycaemia
5%
Type 2 Diabetes Mellitus (T2DM)
5%
Basal Insulin
5%
Glycemic Excursion
5%
Agonist Treatment
5%
Plasma Glucose
5%
Blood Pressure
5%
Diabetes Centre
5%
Dyspepsia
5%
Weight Loss
5%
Hyperglycemia
5%
Treatment Change
5%
Plasma Concentration
5%
Patient Data
5%
Fasting Plasma Glucose
5%
Cholesterol
5%
Intention-to-treat
5%
Subcutaneous Injection
5%
Mixed Models
5%
Efficacy Analysis
5%
Nausea
5%
Insulin Therapy
5%
Steno
5%
Bolus
5%
Saline Solution
5%
One Dose
5%
Add-on Therapy
5%
Placebo Groups
5%
Denmark
5%
Insulin-like
5%
Diarrhea
5%
Novo Nordisk
5%
Medicine and Dentistry
Obesity
100%
Liraglutide
100%
Patient with Type 1 Diabetes
100%
Glycemic Control
100%
Placebo
100%
Glycemic
20%
Hemoglobin A1c
20%
Glucagon
15%
Glucagon Like Peptide 1
15%
Antidiabetic Agent
15%
Hypoglycemia
10%
Stomach Emptying
10%
Glucagon-Like Peptide-1 Agonist
10%
Patient-Reported Outcome
10%
Stomach Acid
5%
Maturity Onset Diabetes of the Young
5%
Hyperglycemia
5%
Subcutaneous Injection
5%
Insulin-Related Peptide
5%
Add on Therapy
5%
Table Salt
5%
Insulin Treatment
5%
Body Mass Index
5%
Glucosulfone
5%
Nausea
5%
Diabetes
5%
Insulin Dependent Diabetes Mellitus
5%
Intention-to-Treat Analysis
5%
Diarrhea
5%
Mixed Model
5%
Patient-Data
5%
Blood Pressure
5%
Pharmacology, Toxicology and Pharmaceutical Science
Liraglutide
100%
Placebo
100%
Insulin Dependent Diabetes Mellitus
100%
Obesity
100%
Hemoglobin A1c
20%
Antidiabetic Agent
15%
Glucagon
15%
Glucagon-Like Peptide-1
15%
Hypoglycemia
10%
Glucagon Like Peptide 1 Receptor Agonist
10%
Subcutaneous Injection
5%
Add on Therapy
5%
Glucosulfone
5%
Stomach Acid
5%
Table Salt
5%
Nausea
5%
Diarrhea
5%
Non Insulin Dependent Diabetes Mellitus
5%
Mixed Model
5%
Hyperglycemia
5%
Immunology and Microbiology
Glycemic Control
100%
Insulin
100%
Glucagon-Like Peptide-1
55%
Stomach Emptying
22%
Agonist
22%
Glucagon
22%
Glucose Blood Level
11%
Stomach Acid
11%
Patient Coding
11%
Solution and Solubility
11%
Glucagon Blood Level
11%
Blood Plasma
11%
Blood Level
11%
Blood Pressure
11%